Clinical Trial Update: Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating thermal ablation combined with anlotinib and TQB2450 (PD-L1 inhibitor) for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hepatocellular Carcinoma, Thermal Ablation | Phase 3 | Status: UNKNOWN